Acorda Therapeutics Inc Provides Update on Tozadenant Development Program - Call
Conference Call Acorda Therapeutics Inc
Acorda Therapeutics Inc Conference call or earnings call will be held on Nov 15, 2017 via an 800 number (toll-free). During the earnings conference call's session Acorda Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Acorda Therapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that restore function and improve the lives of people with neurological disorders. We market three U.S. Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10mg, a treatment to improve walking in patients with multiple sclerosis, or MS, as demonstrated by an increase in walking speed. We also market Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. We have five Orange Book-listed patents providing protection for Ampyra up to 2027. Ampyra also has Orphan Drug designation, which gives it marketing exclusivity in the U.S. until January 2017.Read more Conference Call